21 May 2019 - Objections made on disclosing rebates and revealing data about free samples.
As Washington tries to address soaring drug prices, even efforts to just bring more transparency to the state of affairs aren’t a slam dunk.
At a House subcommittee hearing on Tuesday, interest groups and Republican law makers voiced concerns about bills promising more sunshine.